POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), announced today that patient enrollment for the TIMES 1 trial in the Phase 3 program for Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan has been completed. Referred to as TIMES (Trials of IMeglimin for Efficacy and Safety), the Imeglimin Phase 3 registration program in Japan includes three pivotal trials to evaluate the efficacy and safety of Imeglimin in approximately 1,100 patients.